SI1946776T1 - Stabiliziran tnfr-fc sestavek, ki obsega arginin - Google Patents

Stabiliziran tnfr-fc sestavek, ki obsega arginin

Info

Publication number
SI1946776T1
SI1946776T1 SI200332515A SI200332515A SI1946776T1 SI 1946776 T1 SI1946776 T1 SI 1946776T1 SI 200332515 A SI200332515 A SI 200332515A SI 200332515 A SI200332515 A SI 200332515A SI 1946776 T1 SI1946776 T1 SI 1946776T1
Authority
SI
Slovenia
Prior art keywords
tnfr
arginine
stabilized
composition
methods
Prior art date
Application number
SI200332515A
Other languages
English (en)
Inventor
Wayne R. Gombotz
Richard L. Remmele Jr.
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27766211&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1946776(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corporation filed Critical Immunex Corporation
Priority claimed from EP08006091.6A external-priority patent/EP1946776B1/en
Publication of SI1946776T1 publication Critical patent/SI1946776T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200332515A 2002-02-27 2003-02-27 Stabiliziran tnfr-fc sestavek, ki obsega arginin SI1946776T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36025702P 2002-02-27 2002-02-27
EP08006091.6A EP1946776B1 (en) 2002-02-27 2003-02-27 Stabilized tnfr-fc composition comprising arginine

Publications (1)

Publication Number Publication Date
SI1946776T1 true SI1946776T1 (sl) 2017-07-31

Family

ID=27766211

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200331375T SI1478394T1 (sl) 2002-02-27 2003-02-27 STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
SI200332515A SI1946776T1 (sl) 2002-02-27 2003-02-27 Stabiliziran tnfr-fc sestavek, ki obsega arginin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200331375T SI1478394T1 (sl) 2002-02-27 2003-02-27 STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM

Country Status (16)

Country Link
US (9) US20030180287A1 (sl)
EP (1) EP1478394B1 (sl)
JP (2) JP4583762B2 (sl)
AT (1) ATE402716T1 (sl)
AU (1) AU2003219958B2 (sl)
CA (1) CA2476934C (sl)
CY (1) CY1108361T1 (sl)
DE (1) DE60322513D1 (sl)
DK (2) DK1946776T3 (sl)
ES (2) ES2311094T3 (sl)
HU (1) HUE031630T2 (sl)
MX (1) MXPA04008215A (sl)
PL (1) PL215168B1 (sl)
PT (2) PT1478394E (sl)
SI (2) SI1478394T1 (sl)
WO (1) WO2003072060A2 (sl)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20040157524A1 (en) * 2003-02-06 2004-08-12 The Procter & Gamble Company Fibrous structure comprising cellulosic and synthetic fibers
EP1603596B1 (en) * 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1624846A2 (en) * 2003-05-06 2006-02-15 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
EP2077121B1 (en) * 2003-05-06 2011-02-09 Syntonix Pharmaceuticals, Inc. Clotting factor VII-Fc chimeric proteins for treatment of a hemostatic disorder
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7507745B2 (en) 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
US7655758B2 (en) * 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US20060217311A1 (en) 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
CA2915270C (en) * 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
EP1951305A1 (en) * 2005-11-22 2008-08-06 Wyeth a Corporation of the State of Delaware Immunoglobulin fusion protein formulations
EP1988922A4 (en) * 2006-02-03 2010-06-02 Medimmune Llc PROTEIN FORMULATIONS
FR2899111B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
CN101426817B (zh) * 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
WO2007149334A2 (en) 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
JP2010532790A (ja) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
AU2008334099B2 (en) * 2007-11-30 2014-07-24 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SG10201402265YA (en) * 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
TR201903546T4 (tr) 2009-07-28 2019-04-22 Ge Healthcare Bio Sciences Corp Aşı stabilizatörü.
RU2558821C2 (ru) * 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
RU2012127383A (ru) * 2009-12-02 2014-01-10 Акселерон Фарма Инк. Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке
KR101766936B1 (ko) 2010-01-15 2017-08-09 키린-암젠, 인코포레이티드 항체 제제 및 치료 요법
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
CN105001335B (zh) 2010-03-01 2019-10-25 拜耳医药保健有限公司 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体
WO2011109365A2 (en) 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
JP5911475B2 (ja) 2010-04-26 2016-04-27 ゲノ エルエルシー 超高純度一酸化窒素（ｎｏ）の送達
WO2011134979A2 (en) 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation
EP2568960B1 (en) 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
EP2637690B1 (en) 2010-11-11 2016-09-21 AbbVie Biotechnology Ltd HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
KR20140049961A (ko) 2010-11-29 2014-04-28 갈레온 파마슈티칼스, 인코포레이티드 호흡 조절 장애 또는 질병의 치료를 위한 호흡 자극제로서의 신규 화합물
US9803210B2 (en) 2011-02-11 2017-10-31 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
EP2699265B1 (en) * 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
DK2726090T3 (da) * 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
ES2651483T3 (es) * 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
EP2768532A4 (en) * 2011-10-18 2015-03-11 Coherus Biosciences Inc FORMANTS OF STANOLPT STABILIZED WITH SODIUM CHLORIDE
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US20140302021A1 (en) 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
US9402898B2 (en) 2012-01-23 2016-08-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
EP2822591B1 (en) * 2012-03-07 2018-05-02 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
EA029193B1 (ru) * 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
DK2892550T3 (da) 2012-09-07 2020-03-30 Coherus Biosciences Inc Stabile vandige formuleringer af adalimumab
CN110051823A (zh) 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013336279B2 (en) 2012-10-26 2018-07-19 Lupin Limited Stable pharmaceutical composition of TNFR:Fc fusion protein
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
JP6026002B2 (ja) * 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
KR20150096684A (ko) 2012-12-21 2015-08-25 사노피 엑센딘-4 유도체
EP2949336B1 (en) 2013-01-28 2018-09-05 National University Corporation Kumamoto University Stabilized protein gel preparation
CA2902727C (en) 2013-03-06 2020-08-18 Protalix Ltd. Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy
WO2014136114A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
RU2663727C2 (ru) * 2013-05-02 2018-08-08 Мабксьенсе С.А. Альтернативные составы для химерных полипептидов tnfr:fc
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US10688187B2 (en) 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
RU2698654C2 (ru) 2014-06-13 2019-08-28 Люпин Лимитед Способ очистки белка слияния
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10000551B2 (en) 2014-09-11 2018-06-19 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
KR102534017B1 (ko) 2014-10-23 2023-05-19 암젠 인크 약제학적 제형의 점도 감소
CA2970577A1 (en) 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US11154498B2 (en) * 2015-07-22 2021-10-26 Leiutis Pharmaceuticals Pvt. Ltd. Stabilized liquid formulation of levothyroxine
MX2015010517A (es) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
TWI787161B (zh) 2015-12-18 2022-12-21 日商安斯泰來製藥股份有限公司 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
CN108463470B (zh) * 2015-12-23 2021-10-22 菲尼克斯组织修复公司 胶原蛋白7的组合物及其使用方法
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
WO2018063963A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
WO2018075818A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR20180046888A (ko) 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) * 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EP3710139A4 (en) * 2017-11-13 2021-09-08 Amgen Inc. PROTEIN PRODUCTS PRODUCTION PROCESSES
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
TR201808283A2 (tr) * 2018-06-11 2018-07-23 Centurion Ilac San Ve Tic A S Sulu farmasöti̇k etenersept bi̇leşi̇mi̇
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
GB201901547D0 (en) 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
IL303350A (en) * 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method
WO2022264097A1 (en) 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
CN116643056A (zh) * 2022-02-15 2023-08-25 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
WO2024118481A1 (en) 2022-11-28 2024-06-06 Amgen Inc. Method of processing etanercept

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4360457A (en) 1979-08-30 1982-11-23 Teijin Limited S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010933D1 (de) * 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
WO1993007485A1 (en) * 1991-10-10 1993-04-15 The Regents Of The University Of California Rare immunoglobulin framework regions associated with human disease
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
EP0766564A4 (en) * 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE60005806T2 (de) * 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
CA2366785C (en) * 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
NZ529856A (en) * 1999-10-04 2005-09-30 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
CA2394862C (en) * 1999-12-14 2011-10-11 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
CA2394536A1 (en) * 1999-12-16 2001-06-21 Amgen Inc. Tnfr/opg-like molecules and uses thereof
AU2001236764A1 (en) * 2000-02-10 2001-08-20 Wyeth Method of treating or inhibiting cellular injury or cell death
PT1255558E (pt) * 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
EP1304376A4 (en) * 2000-07-25 2004-12-29 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING RECOMBINANT PROTEIN
DK1314437T3 (da) * 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
US7943146B2 (en) * 2001-12-21 2011-05-17 Myrexis, Inc. Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
EP2699265B1 (en) 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc

Also Published As

Publication number Publication date
EP1478394A4 (en) 2006-03-15
DE60322513D1 (de) 2008-09-11
US8828947B2 (en) 2014-09-09
PL374608A1 (en) 2005-10-31
CA2476934C (en) 2009-06-16
ES2311094T3 (es) 2009-02-01
HUE031630T2 (en) 2017-07-28
US20070243185A1 (en) 2007-10-18
US20030180287A1 (en) 2003-09-25
EP1478394A2 (en) 2004-11-24
ES2618832T3 (es) 2017-06-22
AU2003219958B2 (en) 2006-01-05
US8119604B2 (en) 2012-02-21
CY1108361T1 (el) 2014-02-12
JP2005527503A (ja) 2005-09-15
JP2010106036A (ja) 2010-05-13
EP1478394B1 (en) 2008-07-30
CA2476934A1 (en) 2003-09-04
US9518111B2 (en) 2016-12-13
DK1478394T3 (da) 2008-10-13
MXPA04008215A (es) 2004-11-26
US20220025016A1 (en) 2022-01-27
US20100086559A1 (en) 2010-04-08
PT1478394E (pt) 2008-10-08
ATE402716T1 (de) 2008-08-15
JP4583762B2 (ja) 2010-11-17
SI1478394T1 (sl) 2008-12-31
PT1946776T (pt) 2017-03-17
US11104714B2 (en) 2021-08-31
AU2003219958A1 (en) 2003-09-09
US20140377264A1 (en) 2014-12-25
WO2003072060A3 (en) 2004-03-25
WO2003072060A2 (en) 2003-09-04
US7648702B2 (en) 2010-01-19
DK1946776T3 (en) 2017-03-13
US20190292237A1 (en) 2019-09-26
PL215168B1 (pl) 2013-10-31
US20190144523A1 (en) 2019-05-16
US20120148587A1 (en) 2012-06-14
US20170051039A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
SI1478394T1 (sl) STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
NO20060023L (no) Fast preparat
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
WO2007062399A3 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
WO2006033700A3 (en) Her2 antibody composition
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
NO20020925L (no) N-heterosykliske derivater av NOS-inhibitorer
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
DE602005016532D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
TW200605863A (en) Bazedoxifene acetate formulations
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
WO2007053570A3 (en) A polypeptide complex of trpm8 and calmodulin and its uses thereof
SE0302129D0 (sv) Farmaceutiska kompositioner med antibiotisk aktivitet
ATE259813T1 (de) Triazolopyrimidinderivate
AU2007310767A1 (en) New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90
EP1726311A3 (en) Migration of hematopoietic stem cells and progenitor cells to the liver
EA200300128A1 (ru) Фармацевтические композиции, содержащие карбонат лития
DE60327710D1 (de) Modifizierte zytokine für krebs therapie
AU2003303074A1 (en) Sphingolipid derivatives modified by polyethylene glycol and composition containing the same